Impact of the patient population on the risk for heparin-induced thrombocytopenia

…, P Horsewood, PJ Simpson, JC Moore… - Blood, The Journal …, 2000 - ashpublications.org
The frequency of immune heparin-induced thrombocytopenia (HIT) varies among prospective
studies. It is unknown whether this is caused by differences in the heparin preparations, …

Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin

…, RJ Cook, VJ Marder, JAI Sheppard, JC Moore… - Blood, 2005 - ashpublications.org
Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating IgG antibodies
that recognize platelet factor 4 (PF4) bound to heparin. Immunogenicity of heparins differs in …

Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?

…, JAI Sheppard, JC Moore, KM Moore… - Journal of Laboratory …, 2005 - Elsevier
Heparin-induced thrombocytopenia (HIT) is usually caused by platelet-activating antibodies
of immunoglobulin G class that recognize platelet factor-4 (PF4) bound to heparin or certain …

Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome

TE Warkentin, JC Moore, SS Anand, EM Lonn… - Transfusion medicine …, 2003 - Elsevier
Recent evidence points to isolated deficiency of the largest multimers of von Willebrand
factor (VWF)—known as von Willebrand syndrome type 2A (VWS-2A)—as a risk factor for …

Studies of the immune response in heparin-induced thrombocytopenia

TE Warkentin, JAI Sheppard, JC Moore… - Blood, The Journal …, 2009 - ashpublications.org
Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating antibodies that
recognize PF4/heparin complexes. Uncertainties remain regarding HIT immunobiology, …

[HTML][HTML] Platelet‐activating immune complexes identified in critically ill COVID‐19 patients suspected of heparin‐induced thrombocytopenia

I Nazy, SD Jevtic, JC Moore, A Huynh, JW Smith… - Journal of Thrombosis …, 2021 - Elsevier
Background Thrombocytopenia and thrombosis are prominent in coronavirus disease 2019
(COVID‐19), particularly among critically ill patients; however, the mechanism is unclear. …

Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders

JC Moore, CPM Hayward… - Blood, The Journal of …, 2001 - ashpublications.org
Recent studies investigating thrombotic thrombocytopenic purpura (TTP) have implicated
abnormal plasma von Willebrand factor (vWF)-cleaving metalloprotease activity in this disorder…

The IgG subclasses of platelet‐associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura

H Chan, JC Moore, CN Finch… - British journal of …, 2003 - Wiley Online Library
The majority of patients with idiopathic thrombocytopenic purpura (ITP) have antiplatelet
autoantibodies that are most frequently directed against platelet glycoproteins IIb/IIIa or Ib/IX/V. …

Investigation of anti-PF4 versus anti-PF4/heparin reactivity using fluid-phase enzyme immunoassay for 4 anti-PF4 disorders: classic heparin-induced …

…, DM Arnold, JAI Sheppard, JC Moore… - Journal of Thrombosis …, 2023 - Elsevier
Background Four platelet-activating anti-platelet factor 4 (PF4) disorders have been
recognized: classic heparin-induced thrombocytopenia (cHIT), autoimmune heparin-induced …

Phosphatidylserine externalization and procoagulant activation of erythrocytes induced by Pseudomonas aeruginosa virulence factor pyocyanin

…, DJ Dwivedi, JC Moore… - Journal of cellular …, 2016 - Wiley Online Library
The opportunistic pathogen Pseudomonas aeruginosa causes a wide range of infections in
multiple hosts by releasing an arsenal of virulence factors such as pyocyanin. Despite …